266 related articles for article (PubMed ID: 35435984)
21. A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T-cell therapy.
Cao XY; Zhang JP; Lu Y; Zhao YL; Liu DY; Xiong M; Sun RJ; Wei ZJ; Zhou JR; Zhang X; Yang JF; Li J; Lu P
Br J Haematol; 2024 Apr; ():. PubMed ID: 38613241
[TBL] [Abstract][Full Text] [Related]
22. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.
Cooper ML; DiPersio JF
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101097. PubMed ID: 31779968
[TBL] [Abstract][Full Text] [Related]
23. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF
Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708
[TBL] [Abstract][Full Text] [Related]
24. Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma.
Dai HP; Cui W; Cui QY; Zhu WJ; Meng HM; Zhu MQ; Zhu XM; Yang L; Wu DP; Tang XW
Biomark Res; 2022 Feb; 10(1):6. PubMed ID: 35130959
[TBL] [Abstract][Full Text] [Related]
25. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
[TBL] [Abstract][Full Text] [Related]
26. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
Dai Z; Mu W; Zhao Y; Cheng J; Lin H; Ouyang K; Jia X; Liu J; Wei Q; Wang M; Liu C; Tan T; Zhou J
Signal Transduct Target Ther; 2022 Mar; 7(1):85. PubMed ID: 35332132
[TBL] [Abstract][Full Text] [Related]
27. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL.
Song F; Hu Y; Zhang Y; Zhang M; Yang T; Wu W; Huang S; Xu H; Chang AH; Huang H; Wei G
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36808074
[TBL] [Abstract][Full Text] [Related]
29. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML).
Lu Y; Liu Y; Wen S; Kuang N; Zhang X; Li J; Wang F
J Transl Med; 2022 Dec; 20(1):600. PubMed ID: 36517851
[TBL] [Abstract][Full Text] [Related]
30. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies.
Freiwan A; Zoine JT; Crawford JC; Vaidya A; Schattgen SA; Myers JA; Patil SL; Khanlari M; Inaba H; Klco JM; Mullighan CG; Krenciute G; Chockley PJ; Naik S; Langfitt DM; Mamonkin M; Obeng EA; Thomas PG; Gottschalk S; Velasquez MP
Blood; 2022 Dec; 140(25):2684-2696. PubMed ID: 35914226
[TBL] [Abstract][Full Text] [Related]
31. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential.
Yu Y; Li J; Zhu X; Tang X; Bao Y; Sun X; Huang Y; Tian F; Liu X; Yang L
Int J Nanomedicine; 2017; 12():1969-1983. PubMed ID: 28331319
[TBL] [Abstract][Full Text] [Related]
32. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
34. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Feng C; Dong J; Shen T; Milletti F; Rossi JM; Vezan R; Masouleh BK; Houot R
Lancet; 2021 Aug; 398(10299):491-502. PubMed ID: 34097852
[TBL] [Abstract][Full Text] [Related]
35. Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia.
Zhang C; He J; Liu L; Wang J; Wang S; Liu L; Ge J; Gao L; Gao L; Kong P; Liu Y; Liu J; Han Y; Zhang Y; Sun Z; Ye X; Yin W; Sersch M; Shen L; Cao WW; Zhang X
Blood Cancer J; 2022 Jun; 12(6):96. PubMed ID: 35750687
[TBL] [Abstract][Full Text] [Related]
36. Characteristics and therapeutic approaches for patients diagnosed with T-ALL/LBL exhibiting t(8;14)(q24;q11)/TCRA/D:MYC translocation.
Zhang X; Wang T; Zhang Y; Wang F; Chen J; Ni J; Sun R; Wei Z; Zhang G; Li W; Li J; Lu P
Leuk Lymphoma; 2023 Dec; 64(13):2133-2139. PubMed ID: 37674391
[TBL] [Abstract][Full Text] [Related]
37. Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances.
Liu J; Zhang Y; Guo R; Zhao Y; Sun R; Guo S; Lu W; Zhao M
Front Immunol; 2023; 14():1170968. PubMed ID: 37215124
[TBL] [Abstract][Full Text] [Related]
38. Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells.
Xie L; Gu R; Yang X; Qiu S; Xu Y; Mou J; Wang Y; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Hum Gene Ther; 2023 Dec; 34(23-24):1257-1272. PubMed ID: 37861302
[TBL] [Abstract][Full Text] [Related]
39. A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia.
You F; Wang Y; Jiang L; Zhu X; Chen D; Yuan L; An G; Meng H; Yang L
Am J Cancer Res; 2019; 9(1):64-78. PubMed ID: 30755812
[TBL] [Abstract][Full Text] [Related]
40. CD7 CAR T bridging to allo-HSCT in R/R T-ALL: A case report.
Fanqiao M; Chen X; Ren X; Li L; Wu T
Pediatr Transplant; 2024 May; 28(3):e14367. PubMed ID: 35860981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]